Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4473)	8/14/2001 1:16:43 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Some will remember that ADRX was a pick of our own Jim Silverman, right out of IPO. It's something like a bazillion bagger since then.......... :-) and I got about two or three of them. :-(

To: Biomaven who wrote (4473)	8/14/2001 1:17:56 PM
From: Jibacoa	Respond to of 52153

Thanks for the info. I was familiar with ApoE risk, but was not aware of Avicor's trial on Alzheimers I found also this: Andrx Corporation Announces Results of Alzheimer's Disease Clinical Study April 11, 2001 "Andrx Corporation announced that it has completed a Phase II clinical study that investigated the effects of Avicor on metabolism of beta amyloid protein (A(beta)). Strong evidence from both genetic and biological studies supports the hypothesis that A(beta) is a likely cause of Alzheimer's disease (AD). Data from the study has been incorporated in patent applications and initial results of this study will be published in the International Journal of Neuropsychopharmacology in June 2001. The results demonstrate that Avicor diminishes blood levels of A(beta) in patients with hyperlipidemia. Andrx has recently submitted a New Drug Application for Avicor as a treatment for lipid disorders and has a strong patent position covering statin use in Alzheimer's disease." Bernard